NeoGenomics, Inc. (NEO) — Analyst outlook / Analyst consensus target is. Based on 29 analyst ratings, the consensus is bullish — 1 Strong Buy, 20 Buy, 7 Hold, 1 Sell.
The consensus price target is $13.50 (low: $13.00, high: $14.00), representing an upside of 55.5% from the current price $8.68.
Analysts estimate Earnings Per Share (EPS) of $0.10 and revenue of $0.66B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-3.10 vs est $0.10 (missed -3255.8%). 2025: actual $-4.20 vs est $0.09 (missed -4586%). Analyst accuracy: 0%.
NEO Stock — 12-Month Price Forecast
$13.50
▲ +55.53% Upside
Average Price Target
Based on 29 Wall Street analysts offering 12-month price targets for NeoGenomics, Inc., the average price target is $13.50, with a high forecast of $14.00, and a low forecast of $13.00.
The average price target represents a +55.53% change from the last price of $8.68.
Highest Price Target
$14.00
Average Price Target
$13.50
Lowest Price Target
$13.00
NEO Analyst Ratings
Buy
Based on 29 analysts giving stock ratings to NeoGenomics, Inc. in the past 3 months
EPS Estimates — NEO
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$3.10
vs Est $0.10
▼ 103.2% off
2025
Actual –$4.20
vs Est $0.09
▼ 102.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect the company to turn profitable.
Revenue Estimates — NEO
100%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.661B
vs Est $0.662B
▼ 0.2% off
2025
Actual $0.727B
vs Est $0.726B
▲ 0.2% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
